P2D Bioscience (P2D) is
a specialty pharmaceutical company focused on developing innovative “first in class” drugs for genetic orphan
diseases. P2D currently has a pipeline of three drug candidates, all with novel mechanisms of action. Based in Cincinnati,
Ohio with a satellite office in Mumbai, India we offer capabilities for bringing proprietary molecules through preclinical
efficacy assessment, safety/tox testing, and IND filing in a leveraged schema that de-risks projects and makes even de-prioritized
assets economically feasible for strategic partners. Our therapeutic focus areas are the treatment of central nervous system
(CNS) disorders including orphan central inflammatory disorders, Frontotemporal Dementia, Prader-Willi Syndrome and attention
deficit/hyperactivity disorder (ADHD).
P2D has an experienced drug development team with expertise that
spans preclinical to clinical development including lead optimization, toxicology, pharmacokinetics, safety and regulatory
affairs. Through our strategic partners we have access to GMP manufacture and GLP resources within a risk-sharing model that
maximizes our chances of getting a lead candidate into the clinic.